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Failure of long-term lamivudine prophylaxis in
patients with resolved hepatitis B infection undergo-
ing chemotherapy and allogenic hematopoietic stem
cell transplantation for hematological malignancies:
two case reports 
Hepatitis B virus (HBV) reactivation is a well known
complication in patients with resolved HBV infection,
i.e., HBsAg negative, hepatitis B core antibody (anti-HBc)
positive ± antibodies against HBsAg (anti-HBs), undergo-
ing chemotherapy (CT) and/or allogenic hematopoietic
stem cell transplantation (HSCT) for onco-hematological
diseases.1-3 In these patients, this risk can be prevented by
either “pre-emptive anti-HBV therapy”, based on the
monitoring of HBV DNA and/or HBsAg, followed by res-
cue therapy with anti-HBV regimens, or by “anti-HBV
prophylaxis” based on the administration of
nucleos(t)ides analogs (NUCs) during immunosuppres-
sion and for a consolidation time after the end of
immunosuppressive drugs. As per standard procedure in
our centre, all patients with hematological malignancies
and a resolved HBV infection receive lamivudine (LMV)
prophylaxis at the time of CT or HSCT to be maintained
for at least 18 months after the discontinuation of
immunosuppressive drugs. 
Herein, we describe two patients with resolved HBV
infection who, following allogenic HSCT and repeated
cycles of CT for hematological malignancies, developed
HBsAg seroreversion due to the late emergence of LMV-
resistance (R) during long-term LMV prophylaxis. 
Case A. A 56-year-old Italian male was diagnosed with
micromolecular IgG kappa multiple myeloma (MM) on
June 2008. Since the virological profile was consistent
with a resolved HBV infection with positive anti-HBe and
anti-HBs (240 IU/L) and undetectable serum HBV DNA
(<12 IU/mL), LMV prophylaxis was started concomitant-
ly with CT initiation. Between January 2009 and
December 2010, several cycles of CT were administered
(Table 1 and Figure 1). In December 2010, a matched
unrelated donor (MUD) HSCT was carried out (donor
HBV profile: HBsAg negative, anti-HBs 715 IU/L, anti-
HBc negative) and cysclosporin (CSA) as a prophylaxis
and treatment of graft versus host disease (GvHD) was
started to be progressively reduced and withdrawn in
May 2012. However, in April 2012, MM relapsed requir-
ing further cycles of CT without, nevertheless, achieving
complete disease remission. In November 2015, the
patient was enrolled in a phase I/II trial based on the co-
adminstration of carfilzomib+pomalidomide+dexam-
ethasone. Between 2008 and November 2015, the
patient remained persistently negative for HBsAg, HBeAg
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Table 1. Case A. Chemotherapy regimens and clinical outcomes.
Chemotherapy Time Cycles Early Complications Response
discontinuation
RD (Lenalidomide + dexamethasone) 1 July 08 - 23 Sept 08 4 No None No
Cyclophosphamide 21 Nov 08 1 Yes Spontaneous 5° left rib fracture na
Protocol “MPR vs.Mel 200” 15 Jan 09 - 04 Jun 09 6 Yes Disease progression; 
in MPR arm 
(Melphalan + prednisone + Lenalidomide)
10° left rib fracture after a sneeze na
VD (Bortezomib + dexamethasone) 30 Oct 09 - 11 Dec 09 3 Yes Neutropenia na
PAD 15 Jan 10 - 06 April 10 4 Yes Pneumonia na
(Bortezomib + doxorubicin + dexamethasone)
VD-PACE 16 June 10 - 03 Aug 10 2 Yes Mucositis na
(dexamethasone + Bortezomib + I grade Folliculitis
Platinum Agent + Acute bronchitis
doxorubicin + Cyclophosphamide + 
Etoposide)
Hematopoietic cell transplantation MUD 15 Dec 10 na na Ocular GvHD; 13 April 12 
(Matched Unrelated Donor) Cytomegalovirus reactivation
reactivation. of the disease
RD (Lenalidomide + dexamethasone) 23 May 12 - 16 Nov13 17 Yes Disease na
and 07 March13 - 09 April 13 22 progression
RT (44 Gy)
Bendamustine 15 Jan 14 - 20 May 14 5 Yes Disease progression na
MP (Melphalan + prednisone) 25 June 14 1 Yes No, but new protocol arrived na
Fase I/II protocol LGH447 + BYL719 07 Aug 14 - 26 May15 11 Yes Disease progression na
Fase I/II protocol carfilzomib + 15 Nov 15 - 25 Feb 16 7 Yes Hepatitis B na
pomalidomide + dexamethasone virus reactivation during
Lamivudine prophylaxis
na: not applicable; GvHD: graft-versus-host disease. 
and serum HBV DNA but with, however, a progressive
decline of anti-HBs titers until undetectability in June
2012. For all this period, LMV was maintained owing to
the fact that CT and/or CSA were not withdrawn for
more than 18 months. After 3 months of
carfilzomib+pomalidomide+dexamethasone combina-
tion, HBsAg seroreversion occurred (HBsAg 234 IU/mL)
with detectable HBV DNA (772.850 IU/mL) and HBeAg,
while alanine aminotransferase (ALT) levels remained
within the normal range (19 IU/L). Molecular analysis by
INNO-LIPA HBV Multi-DR confirmed the emergence of
LMV-R (rtL180M, rtM204V). Despite the immediate
switch from LMV to tenofovir disoproxil fumarate (TDF),
serum HBsAg, HBV DNA and ALT increased (qHBsAg
>52.000 IU/mL, HBV DNA 931.575 IU/mL, ALT 69 IU/L)
with otherwise preserved hepatic function. Other possi-
ble causes of the ALT increase, i.e., hepatic GvHD, alco-
hol abuse, intake of herbal products, viral hepatitis other
than HBV, were excluded. On April 2016, the patient
died due to progression of the hematological malignancy
(Figure 1).
Case B. A 64-year-old Italian female with acute
myeloid leukemia (AML) underwent MUD HSCT in
August 2010 (donor HBV profile: HBsAg negative, anti-
HBs 65 IU/L, anti-HBs positive). As the pre-stem cell
transplantation virological profile was consistent with a
resolved HBV infection (HBsAg negative, anti-HBs 62
IU/L, anti-HBc positive, HBV DNA <12 IU/mL), LMV
prophylaxis was started concomitantly with CSA. Due to
AML recurrence on October 2012, she received a salvage
CT regimen which led to a complete remission of the
hematological disease. In April 2013, the patient under-
went a second allogenic HSCT from another matched
unrelated donor (negative for HBsAg, anti-HBs and anti-
HBc) and started CSA which was maintained until July
2015, and seven months (November 2013) after the sec-
ond HSCT the patient developed a suspected liver
GvHD. Owing to incomplete oncological response, a
maintenance treatment with azacitidine was commenced
in April 2014. Between 2010 and February 2016, the
patient maintained a steady virological profile except for
anti-HBs levels which progressively declined reaching
undetectable levels in January 2014 (Figure 2). Despite
LMV prophylaxis, in March 2016 the patient tested posi-
tive for HBsAg (1.2 IU/mL), HBeAg and HBV DNA (32
IU/mL). By April 2016, serum HBsAg increased to 6.5
IU/mL and HBV DNA levels further increased to 6.760
IU/mL (3.83 log10 IU/mL) (Figure 2), and occurrence of
LMV-R (rtV173L, rtM204I) was confirmed by molecular
analysis. Upon administration of TDF, virological mark-
ers progressively improved, HBV DNA rapidly became
undetectable, and HBeAg serocoversion occurred. In
December 2016, HBsAg was positive (70 IU/mL), HBeAg
negative, anti-HBe positive, and serum HBV DNA unde-
tectable (Figure 2).
This report describes two patients with resolved HBV
infection treated with repeated cycles of CT and allo-
genic HSCT for hematological malignancies that failed
long-term LMV prophylaxis and, as a consequence, had
HBsAg seroreversion. As far as we know, this is the first
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Figure 1. Time course of serum ALT and HBV DNA in Case A. RD: lenalidomide+dexamethasone; CYC: cyclophosphamide; MPR:
melphalan+prednisone+lenalidomide; VD: bortezomib+dexamethasone; PAD: bortezomib+doxorubicin+dexamethasone; VP: VD-PACE (dexamethasone+borte-
zomib+platinum agent+doxorubicin+cyclophosphamide+etoposide); allo-HSCT: hematopoietic cell transplantation MUD (matched unrelated donor); CSA:
cyclosporine; RT: radiotherapy; B: bendamustine; MP: melphalan+prednisone; LB: LGH447+BYL719; CPD: carfilzomib+pomalidomide+dexamethasone. 
report of very late onset of LMV-R developing in patients
with resolved HBV infection following heavy immuno-
suppressive therapy for hematological malignancies.
HBV reactivation may hit patients with resolved HBV
infection undergoing CT and/or HSCT, at a rate of up to
50%.1-3 These patients, in fact, harbor low-level transcrip-
tion and replication of HBV in the liver which may flare
up on prolonged exposure to immunosuppressive thera-
pies.4 While management to prevent HBV reactivation in
such patients is not standardized, two available options
include “pre-emptive anti-HBV therapy” and “universal
anti-HBV prophylaxis”. However, patients with lym-
phoma and with resolved HBV infection, HBV reactiva-
tion and severe HBV-related hepatitis were not fully pre-
vented by “pre-emptive anti-HBV therapy” with ente-
cavir (ETV).5-7 Moreover, a randomized controlled study
from Taiwan demonstrated a higher risk of HBV reactiva-
tion among the patients undergoing ETV as “pre-emptive
therapy” compared to those who received this nucleoside
analog as “prophylaxis” (18% vs. 2.4%, P=0.027).8 Similar
findings were confirmed in a Spanish randomized
prospective open label study in which TDF was used.9
Two Italian single center retrospective studies testing
LMV as universal prophylaxis in patients with resolved
HBV infection treated with Rituximab-based CT for NHL
provided conflicting results. The former study demon-
strated that LMV prophylaxis efficiently prevented HBV
reactivation, both during and after withdrawal of CT,
while the second showed a 10% risk of HBV
reactivation.10,11
The risk of HBV reactivation in the onco-hematological
settings requiring HSCT was investigated by a few stud-
ies. A recent Asian retrospective study of 173 patients
with resolved HBV infection undergoing allogenic HSCT
during a median follow up of 21 months showed no sig-
nificant difference in the incidence of HBV reactivation
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Figure 2. Time course of serum ALT and HBV DNA in Case B. CSA: cyclosporine; FLAG-IDA: fludarabine+cytarabine+idarubicin+granulocyte colony-stimulating
factor; ARA-C: cytosine arabinoside high dose.
Table 2. Case B. Chemotherapy regimens and clinical outcomes.
Chemotherapy Time Cycles Early discontinuation Complications Response
FLAG-IDA 16 Oct 12 - 20 Jan 13 2 No None CR
(Fludarabine+cytarabine
+idarubicin
+granulocyte colony-stimulating factor)
ARA-C (Cytosine Arabinoside) 20 Feb 13 1 No None CR
high dose
Azacitidine* 6 April 14 – 7 Nov 16 30 No None CR  
between patients receiving “universal prophylaxis” with
different NUCs and those managed with the “pre-emp-
tive anti-HBV therapy” (5% vs. 5.3%).12 Two studies
among Italian patients with resolved HBV infection
undergoing HSCT reported that LMV prophylaxis effi-
ciently prevented HBV reactivation in the vast majority
of cases.13,14
As recommended by Italian guidelines,15 all patients
referred to our Center due to a resolved HBV infection in
need of CT for lymphoma, MM, AML, acute and chronic
lymphocytic leukemia, and/or allogenic HSCT were con-
sidered for LMV prophylaxis to be maintained for at least
18 months after the end of the immunosuppression. Up
to now, 318 patients have been managed with this
approach and, herein, we report the only two cases
(0.6%) that experienced HBV reactivation. To the best of
our knowledge, these are the first ever reported cases of
LMV-R developing after up to 8 years of prophylaxis in
patients with resolved HBV infection and onco-hemato-
logical malignancies.
The interesting aspect of our report is that despite hav-
ing protective anti-HBs titers and undetectable serum
HBV DNA at baseline, both patients failed LMV after
many years of effective prophylaxis, an event that was
heralded by anti-HBs titer decline during CT and after
HSCT. Boosting the risk of HBV reactivation in our
patients could have been a number of factors, including
the underlying malignancies, the pre-HSCT conditioning
regimen, the intense and repeated cycles of CT including
carfilzomib, bortezomib, pomalidomide, fludarabine, not
to speak of occurrence and severity of GvHD which
required long-term CSA. By contrast, it is unlikely that
the virological profile of the donors played any role in
HBV reactivation as seroconversion occurred many years
after HSCT.
Whether universal prophylaxis with LMV remains the
best option in a setting like this where new potent molec-
ular target drugs are being developed, where the duration
of immunosuppression cannot be easily anticipated, and
where multiple and highly immunosuppressive regimens
may be required, remains unclear. Universal prophylaxis
with third generation NUCs like ETV or TDF in these
patients could be taken into consideration although this
strategy would be more expensive and it is not currently
refunded by many National Health Systems. including
ours. Only long-term prospective studies of large cohorts
of such patients, aimed to define the risk and predictors
of LMV failure, and the cost-effectiveness of LMV in
comparison to ETV or TDF, will shed new light on this
relevant issue.
In conclusion, universal prophylaxis with LMV
monotherapy in patients with resolved HBV infection
undergoing CT and/or HSCT for hematological malig-
nancies is effective and safe but close, long-term virolog-
ical and clinical monitoring is necessary to intercept and
promptly rescue the few HBV reactivations due to viro-
logical breakthrough caused by LMV-resistance. 
Selected onco-hematological patients with MM and
leukemia and resolved HBV infection without oncologic
response who need long-term chemotherapy or those
who underwent HSCT requiring long-term immunosup-
pression due to chronic GvHD and, thereby, in need of
long-term LMV prophylaxis, should be considered at
very high risk of viral reactivation. These patients could
be switched to third generation NUCs after 4 or 5 years
of LMV prophylaxis, as no LMV-R has been reported
before this time point in such a setting. Alternatively,
third generation NUCs could be started as initial prophy-
laxis strategy.
Glenda Grossi,1 Mauro Viganò,2 Floriana Facchetti,1
Sara Labanca,2 Alessandro Loglio,1 Anna Dodero,3
Vittorio Montefusco,3 Paolo Corradini,3 Anna Cafro,4 Roberto
Cairoli,4 Massimo Colombo5 and Pietro Lampertico1
1A. M. and A. Migliavacca” Center for Liver Disease, Division of
Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda
Ospedale Maggiore Policlinico, Università degli Studi di Milano;
2Division of Hepatology, Ospedale San Giuseppe, Università degli
Studi di Milano; 3Dept. Hematology & Pediatric Onco-Hematology,
IRCCS Istituto Nazionale dei Tumori, Università degli Studi di
Milano; 4Dept. of Hematology and Oncology, Niguarda Cancer
Center, Ospedale Niguarda Ca' Granda, Milan and 5Center for
Translational Hepatology Research, IRCCS Humanitas Hospital and
University, Rozzano, Italy
Correspondence: pietro.lampertico@unimi.it
doi:10.3324/haematol.2017.168609
Information on authorship, contributions, and financial & other disclo-
sures was provided by the authors and is available with the online version
of this article at www.haematologica.org.
References
1. Seto WK. Hepatitis B virus reactivation during immunosuppressive
therapy: Appropriate risk stratification. World J Hepatol. 2015;
7(6):825-830. 
2. Raimondo G, Allain JP, Brunetto MR. Statements from the Taormina
expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;
49(4):652-657.
3. Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation
of hepatitis B virus during targeted therapies for cancer and immune-
mediated disorders. Expert Opin Biol Ther. 2016;16(7):917-926.
4. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B
infection. J Hepatol. 2007;46(1):160-170.
5. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B
virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma:
a prospective observational study. Clin Infect Dis. 2015;61(5):719-
729.
6. Tamori A, Hino M, Kawamura E, et al. Prospective long-term study
of hepatitis B virus reactivation in patients with hematologic malig-
nancy. J Gastroenterol Hepatol. 2014;29(9):1715-1721.
7. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B
reactivation in lymphoma patients with resolved HBV infection: A
prospective study. Hepatology. 2014;59(6):2092-2100.
8. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of
entecavir prophylaxis for rituximab-associated hepatitis B virus reac-
tivation in patients with lymphoma and resolved hepatitis B. J Clin
Oncol. 2013;31(22):2765-2772. 
9. Buti M, Manzano ML, Morillas RM, et al. Prevents HBV reactivation
with tenofovir in anti-HBc positive patients withhematological
malignancies treated with rituximab. Results final visit 18-months
(PREBELIN STUDY). J Hepatol. 2016;64(suppl):S369.
10. Viganò M, Grossi G, Borsotti E, et al. Lamivudine prophylaxis pre-
vents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive
patients undergoing Rituximab-based chemotherapy for non-
Hodgkin's B cell lymphoma. J Hepatol. 2015;6(suppl):S566.
11. Castelli R, Ferraris L, Pantaleo G, et al. High rate of hepatitis B viral
breakthrough in elderly non-Hodgkin lymphomas patients treated
with Rituximab based chemotherapy. Dig Liver Dis. 2016;
48(11):1394-1397.
12. Yoo JJ, Cho EJ, Cho YY, et al. Efficacy of antiviral prophylaxis in
HBsAg-negative, anti-HBc positive patients undergoing hematopoi-
etic stem cell transplantation. Liver Int. 2015;35(12):2530-2536.
13. Giaccone L, Festuccia M, Marengo A, et al. Hepatitis B virus reacti-
vation and efficacy of prophylaxis with lamivudine in patients under-
going allogeneic stem cell transplantation. Biol Blood Marrow
Transplant. 2010;16(6):809-817. 
14. Cerva C, Colagrossi L, Maffongelli G, et al. Persistent risk of HBV
reactivation despite extensive lamivudine prophylaxis in
haematopoietic stem cell transplant recipients who are anti-HBc-pos-
itive or HBV-negative recipients with an anti-HBc-positive donor.
Clin Microbiol Infect. 2016;22(11):946.e1-946.e8
15. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treat-
ment of Hepatitis B in immunocompromised patients. Dig Liver Dis.
2007;39(5):397-408.
haematologica 2017; 102:e426
CASE REPORTS
